) recently presented data from studies conducted on Adcetris.
Data was presented at the 12
International Conference on Malignant Lymphoma (ICML).
Seattle Genetics is conducting an investigator-sponsored phase
II study in patients with relapsed or refractory Hodgkin lymphoma
(HL) to examine whether Adcetris can replace the combination
chemotherapy regimen (ifosfamide, carboplatin and etoposide -
ICE) or be used in sequential administration with ICE to increase
the rate of pre-transplant FDG-PET normalization (PET-N). Out of
33 patients that completed this program, 26 patients achieved
Seattle Genetics is conducting a phase II study which is
evaluating Adcetris in CD30-positive non-Hodgkin lymphoma. Out of
22 patients whose response could be evaluated, 6 experienced
complete remission and 2 partial remissions.
Seattle Genetics had presented encouraging phase I data on
Adcetris in mature T-cell lymphoma (MTCL) patients at the
American Society of Hematology (ASH) annual meeting in Dec 2012.
The study showed 100% objective response rate, which includes 88%
Currently, a global phase III study (ECHELON-2) is ongoing.
Adcetris plus chemotherapy is being evaluated for the front-line
treatment of CD30-positive MTCL including patients with systemic
anaplastic large cell lymphoma (sALCL) and other types of
peripheral T-cell lymphomas. The randomized, double-blind,
controlled study will enroll roughly 300 patients and will be
conducted in North America, Europe and Asia.
Seattle Genetics' Adcetris was approved by the FDA in Aug 2011
for the treatment of patients with HL after failure of ASCT or
after failure of at least two prior multi-agent chemotherapy
regimens in patients who are not suitable for ASCT. Adcetris was
also approved for sALCL in treatment-experienced patients.
Seattle Genetics carries a Zacks Rank #3 (Hold). Currently,
Salix Pharmaceuticals Ltd.
) look well positioned in the pharma space with a Zacks Rank #1
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
SEATTLE GENETIC (SGEN): Free Stock Analysis
SALIX PHARM-LTD (SLXP): Free Stock Analysis
SANTARUS INC (SNTS): Free Stock Analysis
To read this article on Zacks.com click here.